5-MAPDB
Systematic (IUPAC) name | |
---|---|
1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine | |
Clinical data | |
| |
Identifiers | |
1354631-78-9 | |
ChemSpider | 26679339 |
Chemical data | |
Formula | C12H17NO |
191.27 | |
SMILES
| |
|
5-MAPDB (1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine) is a chemical compound which might be an entactogenic drug. It is structurally related to drugs like 5-APDB and 5-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 5-MAPDB has never been studied to determine its pharmacological activity, though it is the N-methyl derivative of 5-APDB which is known to be a selective serotonin releaser.[1]
Legality
5-MAPDB was banned in the UK in June 2013 as a temporary class drug along with 9 other related compounds, despite having never been sold as a street drug itself. This was due to concerns that it would have similar effects to drugs such as 5-APB that had been widely sold already, and 5-MAPDB might therefore be likely to become used recreationally also, if it were not banned preemptively.[2]
See also
References
- ↑ Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". Journal of Medicinal Chemistry 36 (23): 3700–6. doi:10.1021/jm00075a027. PMID 8246240.
- ↑ "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. Retrieved 2013-07-11.